Abstract
A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m2 3-h infusion) every 4 weeks in the first line treatment of patients affected by extensive small cell lung cancer. The primary end-point of the trial was the objective response rate. 31 objective responses among 50 patients were considered necessary to proceed to a phase 3 trial. 48 patients were enrolled (median age 59 years). Treatment was very well tolerated. 3 patients (6.2%) had a complete response and 23 (47.9%) a partial response, for an overall response rate of 54.2% (95% CI: 39.2–68.6) Median time to progression was 5.7 months (95% CI: 5.2–6.2). Median survival was 9.6 months (95% CI: 7.2–14.6), with a median follow-up time of alive patients of 12 months. At 1 year, the probability of being progression-free or alive was 0.16 and 0.43, respectively. In conclusion, carboplatin plus paclitaxel as given in the present study is very well tolerated but not sufficiently active to warrant phase 3 comparison with standard chemotherapy regimens. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aisner J, Whitacre M and Abrams J (1986) Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophopshamide and etoposide for small cell lung carcinoma of the lung. J Clin Oncol 3: 54–62
Bishop JF (1992) Carboplatin/etoposide in small cell lung cancer. Oncology 49: 11–18
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756
Cormier Y, Eisenhauer E, Mudal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P and Worg D (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5: 283–285
Deppermann KM, Serke M, Oehm C, Kurzeja A, Riedel U, Lichey HJ, Loddenkemper R, Klockner T and Kettner H (1999) Paclitaxel (TAX) and carboplatin (CBDCA) in advanced SCLC: a phase II study. Proc Am Soc Clin Oncol 18: 482a
Einhorn LH (1986) Initial therapy with cisplatin plus VP-16 in small cell lung cancer. Semin Oncol 13: 5–9
Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH (1995) Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 13: 1430–1435
Evans WK, Eisenhauer E, Hughes P, Maroun JA, Ayoub J, Shepherd FA and Feld R (1988) VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 58: 464–468
Feld R, Evans WK and De Boer (1984) Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 2: 294–304
Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KMW, Shin DM and Hong WK (1999) Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small cell lung carcinoma. J Clin Oncol 17: 2309–2315
Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo C, Monfardini S and Bianco AR (1998) Carboplatin plus vinorelbine, a new well tolerated and active regimen for the treatment of extensive stage small cell lung cancer: a phase II study. J Clin Oncol 16: 1414–1419
Groen HJM, Fokkem E, Biesma B, Kwa B, van Putten JWG, Postmus PE and Smit EF (1999) Paclitaxel and carboplatin in the treatment of small cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non cross resistant schedule. J Clin Oncol 17: 927–932
Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M and Greco FA (1997) Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 15: 3464–3470
Ihde DC (1984) Current status of therapy of small cell carcinoma of the lung. Cancer 2: 2722–2728
Jacobs RH, Bitran J, Deutsch M, Hoffman PC, Sinkule J, Purl S and Golomb HM (1987) Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep 71: 311–312
Jelliffe RW (1973) Creatinine clearance: bedside estimate. Ann Intern Med 79: 604–605
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457–481
Kelly K, Pan Z, Wood ME, Murphy J and Bunn PA, Jr (1999) A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res 5: 3419–3424
Kosmidis PA, Samantas E, Fountzilas G, Paulidis, Apostolopoulou F and Skarlos D (1994) Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 21: 23–30
Lassen U, Kristjansen PEG, Osterlind K, Bargman B, Sisgaard TC, Hirsch FR, Hansen M, Dombernowsky P and Hansen HH (1996) Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy small cell lung cancer. A randomized trial with 5 years follow-up. Ann Oncol 7: 365–371
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Schiller JH, Kim K, Hutson P, De Vore R, Glick J, Stewart J and Johnson D (1998) Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14: 2345–2352
Smith IE and Evans BD (1985) Carboplatin (JM8) as single agent and combination in the treatment of small cell lung cancer. Cancer Treat Rev 12: 73–75
Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR and Ford HT (1987) Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small cell lung cancer. J Clin Oncol 5: 185–189
Thomas P, Lena M, Robinet, Paillotin D, Delaval, Clavier, Bolmes P, Blanchon F, Perdu D, Poirier R, Pommier de Santi P and Kleisbauer JP (1999) Preliminary report on paclitaxel/carboplatin phase II multicentric trial in patients with metastatic small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18: 519a
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Gridelli, C., Manzione, L., Perrone, F. et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 84, 38–41 (2001). https://doi.org/10.1054/bjoc.2000.1541
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1541